Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 26, 2015 9:14 AM ET

Healthcare Equipment and Supplies

Company Overview of AqueSys, Inc.

Company Overview

AqueSys, Inc., an ophthalmic company, focuses on innovating and commercializing implantable devices that improves the treatment of glaucoma. It offers XEN, a gel stent that creates a diffuse outflow of aqueous from the anterior chamber into the non-dissected tissue of the subconjunctival space. The company’s XEN gel stent creates a new pathway to allow the excess fluid in eyes to flow out, and lowers the eye pressure. AqueSys, Inc. was incorporated in 2005 and is based in Aliso Viejo, California. As of October 19, 2015, AqueSys, Inc. operates as a subsidiary of Allergan plc.

26970 Aliso Viejo Parkway

Suite 200

Aliso Viejo, CA 92656

United States

Founded in 2005





Key Executives for AqueSys, Inc.

Chief Executive Officer
Board Observer
Compensation as of Fiscal Year 2015.

AqueSys, Inc. Key Developments

AqueSys Announces Completion of XEN Gel Stent U.S. Clinical Trial Enrollment

AqueSys, Inc. announced the completion of enrollment in the U.S. investigational study of the XEN 45 Gel Stent. The XEN Gel Stent is the first glaucoma device designed to achieve similar intraocular pressure (IOP) reduction as traditional subconjunctival trabeculectomy and tube shunt procedures through a minimally invasive technique with less associated surgical and post-operative risk. The study, a prospective, multicenter single-arm clinical trial conducted at 12 sites within the U.S., is designed to evaluate the safety and performance of the AqueSys XEN 45 Gel Stent in subjects with refractory glaucoma where previous glaucoma treatments were not effective. The company will collect 12-month data on all subjects and submit the data to the U.S. Food and Drug Administration (FDA) to seek market clearance.

Similar Private Companies By Industry

Company Name Region
Hemerus Medical, LLC United States
Clinton Industries, Inc. United States
Ariosa Diagnostics, Inc. United States
CytoSorbents Incorporated United States
Vantage Mobility International, LLC United States

Recent Private Companies Transactions

September 3, 2015

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact AqueSys, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at